Potential therapies that have been proposed for use in the perioperative period in either the murine or clinical setting include immunomodulation (FLT-3, GMCSF,), tumor vaccines, monoclonal antibodies to EGFR, H-2 blockers (shown to inhibit some regulatory T cells), and anti-oxidants with anti-tumor effects such as EGCG (green tea component) and siliphos (milk thistle component) (10, 11, 72–74). This evidence concerns the gene CSF2 and neoplasm.